AZN
AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule CEO Sees 'Significant Value-Inflection Period' Ahead
Article Summary
HOLD- AIM ImmunoTech Inc. (NASDAQ: AIM) surged nearly 42% after announcing its pancreatic cancer trial hit key enrollment milestone ahead of schedule.
- Astrazeneca plc ADR announced final patient enrollment in its Phase 2 study of Ampligen (rintatolimod) combined with AstraZeneca's Imfinzi (durvalumab) following FOLFIRINOX treatment, with CEO Thomas K.
- Equels stating that the company is on track to complete the dosing, which should allow the company to evaluate the study's critical primary endpoint of Clinical Benefit Rate in December 2026.
- The enrollment milestone also marks progress in AIM's broader strategy to advance Ampligen toward late-stage development in pancreatic Cancer, with the company continuing Phase 3 trial planning while expanding its global regulatory and intellectual property footprint.
- The planned Phase 3 program is supported by previously published data from a Dutch government-approved Named Patient Program as well as encouraging results from ongoing DURIPANC study, according to the company.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 9.9% | 25% | 35.0 ptsBelow Screener (9.9%) - Weak growth |
| EPS Growth Next 5Y ? | 12.4% | 25% | 35.0 ptsBelow Screener (12.4%) - Modest outlook |
| Target Price Upside ? | 23.7% | 20% | 70.0 ptsGood Upside (23.7%) - Target: $223.87 vs Current: $180.96 |
| Gross Margin % ? | 74.3% | 15% | 100.0 ptsExceptional (74.3%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -14.9% | 15% | 40.0 ptsMild Pullback (-14.9%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About AZN
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
- The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
- It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines.
- The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases.
- It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia.
- It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.
- The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
- AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.